外科理论与实践 ›› 2022, Vol. 27 ›› Issue (05): 473-477.doi: 10.16139/j.1007-9610.2022.05.018
收稿日期:
2021-04-27
出版日期:
2022-09-25
发布日期:
2022-11-10
通讯作者:
马德奎 审校
E-mail:mdk123@163.com
Received:
2021-04-27
Online:
2022-09-25
Published:
2022-11-10
Contact:
MA Dekui
E-mail:mdk123@163.com
摘要:
Trop2基因在多种恶性肿瘤的发生、发展中起重要作用。三阴性乳腺癌(triple-negative breast cancer, TNBC)的滋养层细胞表面抗原2(trophoblast cell-surface antigen 2, Trop2)基因能调控周期蛋白D1(cyclin D1)及上皮钙黏素的表达,进而促进TNBC转移及侵袭。本文对Trop2基因的结构、功能、作用机制及在TNBC中的表达和治疗进行综述,以期找到TNBC的治疗靶点,探索新疗法。
中图分类号:
王杰强 综述, 马德奎 审校. Trop2基因与三阴性乳腺癌的研究进展[J]. 外科理论与实践, 2022, 27(05): 473-477.
WANG Jieqiang, MA Dekui. Study on trophoblast cell-surface antigen 2 gene and triple-negative breast cancer[J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 473-477.
[1] | Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. |
[2] | Kumar P, Aggarwal R. An overview of triple-negative breast cancer[J]. Arch Gynecol Obstet, 2016, 293(2):247-269. |
[3] | Sharma P. Biology and management of patients with triple-negative breast cancer[J]. Oncologist, 2016, 21(9):1050-1062. |
[4] | McDougall AR, Tolcos M, Hooper SB, et al. Trop2: from development to disease[J]. Dev Dyn, 2015, 244(2):99-109. |
[5] | Cubas R, Zhang S, Li M, et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway[J]. Mol Cancer, 2010, 9:253. |
[6] | 张喆, 贾立周, 唐奇, 等. TROP2和VEGFR2在三阴性乳腺癌中的表达及与临床病理因素的相关性研究[J]. 南京医科大学学报(自然科学版), 2019, 39(10):1453-1458. |
[7] | Li X, Teng S, Zhang Y, et al. TROP2 promotes prolife-ration, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT[J]. Oncotarget, 2017, 8(29):47052-47063. |
[8] | Vidmar T, Pavšiŏc M, Lenarŏciŏc B. Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain[J]. Protein Expr Purif, 2013, 91(1):69-76. |
[9] | Lin JC, Wu YY, Wu JY, et al. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma[J]. EMBO Mol Med, 2012, 4(6):472-485. |
[10] | Cubas R, Li M, Chen C, et al. Trop2: a possible therapeutic target for late stage epithelial carcinomas[J]. Biochim Biophys Acta, 2009, 1796(2):309-314. |
[11] | Guerra E, Lattanzio R, La Sorda R, et al. mTrop1/Epcam knockout mice develop congenital tufting enteropathy through dysregulation of intestinal E-cadherin/β-catenin[J]. PLoS One, 2012, 7(11):e49302. |
[12] | McDougall AR, Hooper SB, Zahra VA, et al. The oncogene Trop2 regulates fetal lung cell proliferation[J]. Am J Physiol Lung Cell Mol Physiol, 2011, 301(4):L478-L489. |
[13] | Xie J, Mølck C, Paquet-Fifield S, et al. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells[J]. Oncotarget, 2016, 7(28):44492-44504. |
[14] | Guan H, Guo Z, Liang W, et al. Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways[J]. BMC Cancer, 2017, 17(1):486. |
[15] | Liu T, Liu Y, Bao X, et al. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway[J]. PloS One, 2013, 8(9):e75864. |
[16] | Vermeulen K, van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer[J]. Cell Prolif, 2003, 36(3):131-149. |
[17] | 葛亚楠, 朱欢欢, 韩涛, 等. 细胞周期蛋白在三阴型和激素依赖型乳腺癌中的差异表达及临床意义[J]. 解放军医药杂志, 2016, 28(6):27-32. |
[18] | 张影. 抗Cyclin D1胞内抗体对三阴性乳腺癌生长和转移的抑制作用及机制研究[D]. 吉林: 吉林大学, 2020. |
[19] | Guerra E, Trerotola M, Aloisi AL, et al. The Trop-2 signalling network in cancer growth[J]. Oncogene, 2013, 32(12):1594-1600. |
[20] | Zhao W, Kuai X, Zhou X, et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer[J]. Oncol Rep, 2018, 40(2):759-766. |
[21] | Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis[J]. Genes Dev, 2013, 27(20):2192-2206. |
[22] | Sahota S, Vahdat LT. Sacituzumab govitecan: an antibody-drug conjugate[J]. Expert Opin Biol Ther, 2017, 17(8):1027-1031. |
[23] | Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors[J]. Clin Cancer Res, 2015, 21(17):3870-3878. |
[24] | Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8):741-751. |
[25] | Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16):1529-1541. |
[26] | van Rij CM, Lütje S, Frielink C, et al. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody[J]. Eur J Nucl Med Mol Imaging, 2013, 40(9):1377-1383. |
[27] | Updated clinical results and new biomarker analyses presented for Daiichi Sankyo′s DS-1062 in patients with advanced NSCLC at 2019 World Conference on Lung Cancer[EB/OL]. [2019-09-10]. . |
[28] | 李群. SKB264在局部晚期或转移实体瘤患者中的开放、国际多中心Ⅰ-Ⅱ期首次人体试验(FIH)的初步结果[EB/OL]. [2021-04-27]. . |
[1] | 邢颖, 程石. 胆囊癌新辅助治疗的现状和争议[J]. 外科理论与实践, 2023, 28(02): 110-114. |
[2] | 王远江, 邹浩. 胆囊癌综合治疗的临床研究[J]. 外科理论与实践, 2023, 28(02): 171-176. |
[3] | 杨崔燕, 王豪雨, 陈小松, 沈坤炜. 抑癌基因TP53突变状态与三阴性乳腺癌病人预后的研究[J]. 外科理论与实践, 2022, 27(05): 421-428. |
[4] | 李佳, 吕良敬. 靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303. |
[5] | 黄乃思, 陈嘉莹, 嵇庆海, 王宇. 靶向药物时代局部晚期甲状腺癌的新辅助治疗[J]. 外科理论与实践, 2021, 26(06): 493-496. |
[6] | 常宇宸, 宋陆茜. B细胞淋巴瘤2抑制剂在髓系肿瘤治疗中的机制研究及应用进展[J]. 内科理论与实践, 2021, 16(04): 272-275. |
[7] | 冯秀娟, 吴涛, 白海. 急性髓系白血病DNA异常甲基化及治疗进展[J]. 内科理论与实践, 2021, 16(04): 282-286. |
[8] | 刘泓源, 杨希, 顾豪, 胡丽, 孙怡, 陈辉, 林晓曦. 1例复杂静脉畸形的靶向治疗[J]. 组织工程与重建外科杂志, 2020, 16(3): 198-200. |
[9] | 刘泓源, 葛同鑫, 林晓曦. 静脉/淋巴管畸形靶向治疗的研究进展[J]. 组织工程与重建外科杂志, 2020, 16(3): 204-209. |
[10] | 钱梨寒, 沈柏用. 局部进展期胰腺癌综合治疗的研究进展[J]. 外科理论与实践, 2020, 25(05): 442-446. |
[11] | 张俊, 姜毓, 沈柏用. 胰腺神经内分泌肿瘤的治疗[J]. 外科理论与实践, 2019, 24(03): 208-211. |
[12] | 马韵芳, 潘丽娜, 张培培, 何清, 徐志红, 胡家安. 人类表皮生长因子受体2基因扩增的非小细胞肺癌一例报告[J]. 诊断学理论与实践, 2018, 17(04): 462-465. |
[13] | 赵莉娟,郑江红,柳向东,茅广宇,邓辰亮,杨松林. iRGD-外泌体-阿霉素抑制恶性黑色素瘤体外增殖的研究[J]. 组织工程与重建外科杂志, 2017, 13(1): 25-28. |
[14] | 梁贇, 姜翀弋, 王巍,. 胰腺癌的靶向治疗[J]. 外科理论与实践, 2017, 22(01): 84-88. |
[15] | 金薇, 罗祎, 刘溦薇, 陈国庆, 周鸣,. microRNA-130b促进三阴性乳腺癌细胞及其作用机制[J]. 外科理论与实践, 2017, 22(01): 49-56. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||